Live
FierceBiotechTakeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdownEndpoints NewsTakeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3Endpoints NewsNeion Bio raises $23M Series A to make proteins from chicken eggsClinical OMICsApp-Controlled “Wound Zipper” Aids Bespoke Skin HealingEndpoints NewsExclusive: Genentech closes infectious disease unit in wave of research layoffs10x Genomics Blog10x Genomics Acquires Proteintech Genomics To Expand Proteomics Capabilities - Pulse 2.0IlluminaIllumina upgraded to overweight at JPMorgan on clinical demand outlook - Investing.comEndpoints NewsRare disease biotech Beren adds $300M from new financingsClinical OMICsAI Tool Classifies 102 CNS Tumor Subtypes in MinutesClinical OMICsFast-Acting Malaria Drug Shows Promise in First-in-Human StudyClinical OMICsUltrasensitive HPV DNA Blood Test Could Help Personalize Head and Neck Cancer TreatmentClinical OMICsDigital Portal Strengthens Patient Engagement in Cancer Clinical Trials
Recursion Apr 16, 2026

Is Recursion Pharmaceuticals (RXRX) Turning Conference Spotlights Into a Durable AI Drug Discovery Edge? - simplywall.st

Is Recursion Pharmaceuticals (RXRX) Turning Conference Spotlights Into a Durable AI Drug Discovery Edge? - simplywall.st

Body unavailable. Use the original source.